Abstract

Urinary tract infection (UTI) one of the most common infectious diseases has been seen as a global burden. Escherichia coli (E. coli) is responsible for causing majority of the UTIs. This study was conducted at Kantipur Hospital Pvt. Ltd. Kathmandu from July 2016 to December 2017.The research was conducted to study about the relation between pyuria and bacteriuria among patients suspected of urinary tract infection. A total of 464 mid-stream urine samples were collected. Out of total processed sample 97/464 was positive while 263 were culturally negative. E. coli accounted for 76.28 %( 74) of the growth while K. pneumoniae accounted for 9.27% (9) of the total bacterial growth. Other organism which were found were P. vulgaris 8.24 (8) S. aureus 3.09 %( 3), Coagulase negative staphylococcus (CoNS) 1.03% (1), E. facealis1.03% (1) and P. aeruginosa 1.03% (1). Amikacin was most susceptible drugs for E. coli with 90.54% (67) success followed by gentamicin 81.08 %( 60). Both amikacin and gentamicin proved susceptible for other gram negative isolates too. Among the total isolates 73 of them were found to Multi Drug Resistant (MDR) were E. coli 92.85% (66) has most number of MDR cases followed by 3.96 %( 4).It was found that female patient were more affected (79) than male patient (18).While on age group basis people aging between 21-30 years mostly had infection (31). Among the 464 samples, 78.67% (365) of samples showed insignificant pyuria. However, 4.12% of samples gave positive culture results. The highest Culture positivity, 28 (75.67%) samples out of 37 was detected in urine samples having pus cells of 6-10/hpf, whereas 5(33.33%) urine samples with more han 50 pus cells/hpf was culture positive. Female are more susceptible for UTI than Male and presence of pyuria can be good indicator of urine infection, though Culture should always be considered as gold standard.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call